Peregrine Pharmaceuticals (PPHM) will announce data from a mid-stage study of its ... There's been a lot of speculation about the drug, leading to considerable volatility in the stock. The shares traded as low as $.40 earlier this year, but …
Its stock fell 0.9 percent to $90.87 and was the top drag on the ... Among the largest decliners on Monday was Peregrine Pharmaceuticals Inc PPHM.O, which plunged 78.5 percent to $1.16 after the company said it found major …
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk …
Each of these rates a “D” (“sell”) or “F” overall (“strong sell”). Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures.
The company’s common stock and preferred stock will continue to trade under the ticker symbols “PPHM” and “PPHMP”, respectively, until market close on Friday, January 5, 2018. The corporate name change to Avid Bioservices does not …
The stock has traded in a 52-week range of $1.15 to $2.43 a share, rising about 12.3% over the past 12 months. In other sector news, (-) PPHM, Reports fiscal Q4 net loss of $10.6 mln, or $0.06 per share, up from an $8.4 mln net loss in the …
NICE Systems (NASDAQ: NICE) announced that it won a mega security contract from a government agency. The …
Peregrine, which develops cancer treatments, will trade under the symbol PPHM starting today ... Company shares closed at $2.59 Monday, up 25 cents in Nasdaq trading. The stock has gained 388% since the beginning of the year, but has …
Jan 12 (Reuters) - Peregrine Pharmaceuticals Inc. PPHM.O said it filed a shelf registration statement to sell upto $30 million of its common stock. The company plans to use the proceeds to support further development of its preclinical …